Avatrombopag: A Review in Thrombocytopenia
| Autor: | Anthony Markham |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Excessive Bleeding medicine.medical_specialty Thiophenes Chronic liver disease Placebo Gastroenterology Adis Drug Evaluation Pharmacotherapy hemic and lymphatic diseases Internal medicine medicine Animals Humans Pharmacology (medical) Platelet Thrombopoietin Purpura Thrombocytopenic Idiopathic business.industry Liver Diseases Correction medicine.disease Thrombocytopenia Clinical trial Thiazoles Platelet transfusion Chronic Disease business Receptors Thrombopoietin |
| Zdroj: | Drugs |
| ISSN: | 1179-1950 0012-6667 |
| DOI: | 10.1007/s40265-021-01613-y |
| Popis: | Avatrombopag (Doptelet®) is an orally administered second generation thrombopoietin receptor agonist (TPO-RA) approved for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory or have an unsatisfactory response to other treatments, as well as for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled to undergo an invasive procedure. In phase III studies, avatrombopag was associated with a significantly greater platelet response than placebo in patients with chronic ITP, and was superior to placebo in reducing the requirement for platelet transfusion or rescue procedures for bleeding caused by surgery in patients with CLD with a platelet count Plain Language Summary Avatrombopag (Doptelet®) is an orally administered drug that mimics the natural compound (thrombopoietin) responsible for stimulating the production of platelets, an essential component of the clotting process that prevents excessive bleeding. Several conditions can cause reduced platelet levels (thrombocytopenia) to the point that intervention is needed to prevent excessive blood loss. Avatrombopag is approved for the treatment of primary chronic immune thrombocytopenia (ITP) and to prevent bleeding caused by surgery in patients with low platelet levels caused by chronic liver disease (CLD). Clinical trials in patients with ITP show that avatrombopag quickly increases platelet levels and that this increase is maintained in the longer term in many patients. Similarly, clinical trials in patients with low platelet levels because of CLD showed that giving avatrombopag prior to surgery reduced the need for platelet transfusions or rescue procedures for bleeding. Avatrombopag is thus a convenient and effective treatment for patients with chronic ITP and can prevent bleeding events in patients with CLD scheduled to undergo a procedure. In both indications avatrombopag offers a useful alternative to other available treatments. Supplementary Information The online version contains supplementary material available at 10.1007/s40265-021-01613-y. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink